THE ULCERATIVE COLITIS MARKET SIZE WAS VALUED AT USD 7.24 BILLION IN 2021 AND IS EXPECTED TO REACH USD 12 BILLION BY 2027, GROWING AT A CAGR OF 8.77% DURING 2022-2027.

The Ulcerative Colitis Market Size, Share, Trends Analysis

  • Drug Class: TNF-Alpha inhibitors, 5-Aminosalicylates, Corticosteroids & Others
  • Gender Type: Men and Women
  • Disease Type: Total Colitis, and Left-sided Colitis & Proctitis
  • Geography: North America, Europe, and APAC

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022-2027

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

219 Pages

icon-table

9 Tables

icon-chart

134 Charts

icon-region

3 Regions

icon-country

8 Countries

icon-company

10 Companies

icon-market

4 Market Segment

ULCERATIVE COLITIS MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 12 Billion
Market Size (2021) USD 7.24 Billion
CAGR (2022-2027) 8.77%
Base Year 2021
Forecast Year 2022-2027
Market Segments Drug Class, Gender Type, Disease Type, and Geography
Geographic Analysis North America, Europe, and APAC
Countries Covered US, France, Germany, Italy, UK, Spain, China, and Japan

MARKET OVERVIEW

The ulcerative colitis market was valued at USD 7.24 billion in 2021 and is expected to reach USD 12 Billion by 2027, growing at a CAGR of 8.77% from 2022 to 2027. Ulcerative colitis is a chronic inflammatory bowel disease (IBD) in which abnormal immune system reactions cause inflammation and ulcers on the inner lining of the large intestine. The ulcerative colitis epidemiology provides insights into the historical and current patient pools and forecasted trends for eight (8MM) major countries. The ulcerative colitis segment covers the historical and forecasted epidemiology data in the US, EU5 (including France, Germany, Italy, Spain, and the UK), China, and Japan from 2021-2027. The Ulcerative colitis epidemiology data are studied through all possible divisions to give a better understanding of the disease scenario in 8MM.

This report provides a detailed analysis of the drugs available for the treatment of ulcerative colitis. The report covers a detailed drug description including drug name, sponsor name, route of administration, molecule type, mechanism of action of the drug, clinical studies, NDA approvals, and Ulcerative colitis (Ulcerative colitis) collaborations, licensing, mergers and acquisition, designations, and other product-related details.

According to Arizton's estimate, the diagnosed incident cases ofinflammatory bowel disease were high in the United States, followed by China and the UK in 2020. The increasing prevalence of ulcerative colitis is driving the growth of the ulcerative colitis drug market. According to the estimates, one million people were affected by inflammatory bowel disease in the US in 2019.

MARKET DRIVERS

Launch of New Therapies: The USFDA approved small molecules such as Jyseleca (Filgotinib) and Rinvoq (Upadacitinib) in 2022 to treat moderate-to-severe ulcerative colitis. The launch of approved small molecules and further uptake in biological therapies will lead to significant growth in the ulcerative colitis therapeutics market.

Increasing Prevalence of Ulcerative Colitis: The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of inflammatory bowel disease worldwide. According to the estimates, the prevalence of inflammatory bowel disease patients was 910,000 in the United States in 2018.

MARKET TRENDS

High Investment in R&D Activities: Major players in the market are developing products and spending significantly on research and development, along with major acquisitions and collaborations to achieve a competitive edge over their counterparts. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market.

Presence of Major Players: Companies such as AbbVie, Inc., Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson) are among the major players in the global ulcerative colitis treatment market. These players are focused on adopting organic and inorganic growth strategies to strengthen their product portfolio.

These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global ulcerative colitis treatment market. The other prominent players operating in the global ulcerative colitis market include Allergan plc, Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, Novartis AG, Galapogos, and Seres Therapeutics.

GEOGRAPHY ANALYSIS

The US dominates the ulcerative colitis market due to the rise in healthcare affordability in the US, the rise in knowledge and awareness amongst the people, and the technological advancement in this region. However, the UK is expected to grow at a faster rate with a high CAGR in the ulcerative colitis drug market due to a rise in access and quality of healthcare, an increase in awareness about disease management, and rising healthcare expenditure in this region. The trend of biosimilars in emerging markets, such as China and Japan, could potentially alter the therapeutic landscape in this region.

Drug Class: Among the drug class, TNF-Alpha inhibitors are expected to account for a significant share of the global ulcerative colitis therapeutics market. However, the other class of drugs is expected to be the fastest-growing segment during the forecast period. Recently approved small molecules such as Jyseleca (filgotinib) and Rinvoq (upadacitinib) are expected to drive the global ulcerative colitis therapeutics market during the forecast period.

Gender type: Among the gender type, Men were expected to account for a significant share of the global ulcerative colitis market. This is due to men being more likely affected than women.

Disease type: Among the Disease type, Total colitis is expected to account for significant ulcerative colitis market share. However, Proctitis is expected to be the fastest-growing segment during the forecast period.

The portfolio contains a total of 106+ assets in various development phases. Most industry-sponsored drugs in active clinical development for ulcerative colitis are in the Phase II stage.

ULCERATIVE COLITIS THERAPEUTICS: CLINICAL TRIALS SCENARIO

 The clinical trial portfolio contains 155+ trials in various development phases. Most industry-sponsored drugs in active clinical development for inflammatory bowel disease are in Phase II, with three drugs in the NDA/BLA stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ulcerative colitis have been in the early and mid-phases of development, with 84% of trials in Phase I-II and only 16% in Phase III-IV. The US has a substantial lead in the number of ulcerative colitis clinical trials globally.

COMPETITIVE SCENARIO

The Ulcerative Colitis market is dominated by companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating UC. The US Food and Drug Administration (FDA) approved the TNF-Alpha agent Humira (Adalimumab) for treating ulcerative colitis in 2012. This marked the arrival of biologics in this treatment landscape. Following this, the FDA approved Jyseleca (filgotinib) and Rinvoq (upadacitinib) in 2022 and Zeposia (ozanimod) in 2021 for the treatment of UC. Although generic products continue to capture significant market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.

The inflammatory bowel disease therapeutics portfolio contains a total of 106+ assets in various development phases. Some late-stage emerging inflammatory bowel disease Therapeutics include AJM-300, ontamalimab, CT-P13 SC, SHR-0302, mirikizumab, and others. Launching these novel emerging drugs will shift the inflammatory bowel disease treatment paradigm shortly. With more than 106 molecules in various stages of development, it is expected that new vendors are likely to enter the market with novel mechanisms of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating ulcerative colitis. Key vendors are likely to face stiff competition from emerging players whose drugs are in various stages of development for UC. Existing vendors need to compete with more than 90 vendors post the approval of their investigational molecules for inflammatory bowel disease treatment in the coming years.

The prominent players offering drugs in the market include Takeda, Abbvie, Janssen Pharmaceuticals, Pfizer, Bristol-Myers-Squibb,  EA Pharma Co Ltd, Celltrion, ReiStone Biopharma, Eli Lilly and Company, and Index Pharmaceuticals. These players are focused on R&D initiatives to develop technologically advanced and innovative inflammatory bowel disease treatment drugs and are also entering into collaborations to maintain their market position.

REPORT COVERAGE

  • Detailed overview of ulcerative colitis, including disease definition, classification, diagnosis, and treatment pattern
  • Overview of the global ulcerative colitis market trend in the eight major markets.
  • Historical, current, and projected patient pool of ulcerative colitis in the eight major markets (8MM) for the 2018 – 2027 period
  • Gender type, Disease type, Drug Class, and Geography type segmentation of the ulcerative colitis in the eight major markets (8MM)
  • Historical, current, and projected market size of inflammatory bowel disease treatment market in the eight major markets (8MM) for the 2018 – 2027 period
  • In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
  • Market share of the market players, company profiles, product specifications, and competitive landscape
  • Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
  • Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
  • Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for ulcerative colitis across the complete product development cycle, including all clinical and non-clinical stages
  • Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and Geography type for ulcerative colitis across all clinical stages
  • Coverage of dormant and discontinued pipeline projects and the reasons for ulcerative colitis.
  • Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the ulcerative colitis space.

Frequently Asked Questions

HOW BIG IS THE GLOBAL ULCERATIVE COLITIS MARKET?

The global ulcerative colitis market is expected to reach USD 12 billion by 2027.

WHAT IS THE GROWTH RATE OF THE GLOBAL ULCERATIVE COLITIS MARKET?

The global ulcerative colitis market is expected to grow at a CAGR of 8.77% from 2022 to 2027.

WHO ARE THE KEY PLAYERS IN THE ULCERATIVE COLITIS (UC) MARKET?

Johnson & Johnson, AbbVie Inc (AbbVie), Takeda Pharmaceutical Co Ltd (Takeda), Pfizer Inc (Pfizer), Bristol-Myers Squibb, EA Pharma, Eli Lilly and Company, InDex Pharmaceuticals, Reistone Biopharma Co. Ltd., and CellTrion.

WHAT ARE THE GROWTH FACTORS IN THE ULCERATIVE COLITIS MARKET?

The launch of new therapies and the high prevalence of ulcerative colitis is the growth factors in the market.

Download Free Sample

The ulcerative colitis market was valued at USD 7.24 billion in 2021 and is expected to reach USD 12 Billion by 2027, growing at a CAGR of 8.77% during 2022-2027.

The following factors will drive the ulcerative colitis market growth during the forecast period:

  • Launch Of New Therapies
  • High Prevalence of UC
  • High Investment in Research & Development  

Base Year: 2021

Forecast Year: 2022-2027

The study considers a detailed scenario of the present global ulcerative colitis market and its dynamics for the forecasted period. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the industry. 

Key Vendors

  • Johnson & Johnson
  • AbbVie Inc (AbbVie) 
  • Takeda Pharmaceutical Co Ltd (Takeda)
  • Pfizer Inc (Pfizer)
  • Bristol-Myers Squibb
  • EA Pharma
  • Eli Lilly and Company
  • InDex
  • Reistone Biopharma Co. Ltd. 
  • CellTrion

Segmentation by Drug Class

  • TNF-Alpha inhibitors
  • 5-Aminosalicylates
  • Corticosteroids & Others

Segmentation by Gender Type

  • Men
  • Women

Segmentation by Disease Type

  • Total Colitis
  • Left-sided Colitis & Proctitis

Segmentation by Geography

  • North America
    • US
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
  • APAC
    • China
    • Japan

For more details, please reach us at enquiry@arizton.com

For more details, please reach us at enquiry@arizton.com

Select a license type that suits your business needs

single-user Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date